Physician profile
Hammad Siddiqui
NPI 1497205843
$3,192.47
in general payments reported to CMS, 2019-2025
26 companies · $842 in 2025
The $842 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $474 · 2022: $544 · 2023: $878 · 2024: $455 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,072 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,072.35 |
| Education | $102.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $460.24 | 2022-2025 | Krystexxa, Tavneos, Uplizna |
| Travere Therapeutics, INC. | $239.57 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $230.00 | 2021-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $227.38 | 2021-2025 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $211.86 | 2021-2025 | Terlivaz, Acthar |
| Otsuka America Pharmaceutical, INC. | $208.41 | 2021-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $195.85 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $189.42 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $164.45 | 2023-2025 | |
| Ardelyx, INC. | $136.83 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $128.56 | 2021-2025 | Shingrix, Arexvy |
| Alexion Pharmaceuticals, INC. | $128.29 | 2021-2024 | Ultomiris |
| Aurinia Pharma U.S., INC. | $125.36 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $99.27 | 2022-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $81.49 | 2021-2023 | Velphoro, Korsuva |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $52.69 | 2021-2024 | |
| Ultragenyx Pharmaceutical INC. | $47.71 | 2023 | |
| Emd Serono, INC. | $43.88 | 2021 | |
| Daiichi Sankyo INC. | $40.05 | 2023-2024 | Enhertu, Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.20 | 2025 | Jardiance |
| Lilly USA, LLC | $35.09 | 2023-2025 | Jardiance |
| Akebia Therapeutics INC | $34.11 | 2021 | |
| Nxstage Medical, INC. | $24.04 | 2025 | Liberty Select Cycler, Nxstage System One |
| Alkermes, INC. | $22.78 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.10 | 2023 | Gattex |
| Xeris Pharmaceuticals, INC. | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hammad Siddiqui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.